JP2018500896A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018500896A5 JP2018500896A5 JP2017530591A JP2017530591A JP2018500896A5 JP 2018500896 A5 JP2018500896 A5 JP 2018500896A5 JP 2017530591 A JP2017530591 A JP 2017530591A JP 2017530591 A JP2017530591 A JP 2017530591A JP 2018500896 A5 JP2018500896 A5 JP 2018500896A5
- Authority
- JP
- Japan
- Prior art keywords
- rodent
- polypeptide
- gene
- human
- endogenous
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 241000283984 Rodentia Species 0.000 claims description 134
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 claims description 108
- 102000048776 human CD274 Human genes 0.000 claims description 55
- 238000000034 method Methods 0.000 claims description 40
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims description 37
- 101150091609 CD274 gene Proteins 0.000 claims description 36
- 101100407305 Homo sapiens CD274 gene Proteins 0.000 claims description 36
- 150000001413 amino acids Chemical class 0.000 claims description 16
- 210000004027 cell Anatomy 0.000 claims description 16
- 210000001671 embryonic stem cell Anatomy 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 11
- 230000003834 intracellular effect Effects 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 7
- 229940079593 drug Drugs 0.000 claims description 7
- 230000004614 tumor growth Effects 0.000 claims description 4
- 210000001161 mammalian embryo Anatomy 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 210000004881 tumor cell Anatomy 0.000 claims description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 16
- 150000007523 nucleic acids Chemical group 0.000 claims 16
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 238000012216 screening Methods 0.000 claims 1
- 102000008096 B7-H1 Antigen Human genes 0.000 description 17
- 108010074708 B7-H1 Antigen Proteins 0.000 description 17
- 108700024394 Exon Proteins 0.000 description 14
- 239000002773 nucleotide Substances 0.000 description 7
- 125000003729 nucleotide group Chemical group 0.000 description 7
- 229920001184 polypeptide Polymers 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 125000003275 alpha amino acid group Chemical group 0.000 description 5
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 description 4
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 3
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 102000048362 human PDCD1 Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 1
- 101100407306 Mus musculus Cd274 gene Proteins 0.000 description 1
- 101001117316 Mus musculus Programmed cell death 1 ligand 1 Proteins 0.000 description 1
- 229940122862 PD-L1 agonist Drugs 0.000 description 1
- 229940123751 PD-L1 antagonist Drugs 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462089549P | 2014-12-09 | 2014-12-09 | |
| US62/089,549 | 2014-12-09 | ||
| US201562106525P | 2015-01-22 | 2015-01-22 | |
| US62/106,525 | 2015-01-22 | ||
| PCT/US2015/064626 WO2016094481A1 (en) | 2014-12-09 | 2015-12-09 | Non-human animals having a humanized cluster of differentiation 274 gene |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020168478A Division JP7145920B2 (ja) | 2014-12-09 | 2020-10-05 | ヒト化分化抗原群２７４遺伝子を有する非ヒト動物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018500896A JP2018500896A (ja) | 2018-01-18 |
| JP2018500896A5 true JP2018500896A5 (enExample) | 2019-01-24 |
Family
ID=55024286
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017530591A Withdrawn JP2018500896A (ja) | 2014-12-09 | 2015-12-09 | ヒト化分化抗原群２７４遺伝子を有する非ヒト動物 |
| JP2020168478A Active JP7145920B2 (ja) | 2014-12-09 | 2020-10-05 | ヒト化分化抗原群２７４遺伝子を有する非ヒト動物 |
| JP2022148949A Active JP7488861B2 (ja) | 2014-12-09 | 2022-09-20 | ヒト化分化抗原群２７４遺伝子を有する非ヒト動物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020168478A Active JP7145920B2 (ja) | 2014-12-09 | 2020-10-05 | ヒト化分化抗原群２７４遺伝子を有する非ヒト動物 |
| JP2022148949A Active JP7488861B2 (ja) | 2014-12-09 | 2022-09-20 | ヒト化分化抗原群２７４遺伝子を有する非ヒト動物 |
Country Status (27)
| Country | Link |
|---|---|
| US (4) | US9913461B2 (enExample) |
| EP (3) | EP4399969A3 (enExample) |
| JP (3) | JP2018500896A (enExample) |
| KR (2) | KR102316842B1 (enExample) |
| CN (2) | CN113412818B (enExample) |
| AU (3) | AU2015360667B2 (enExample) |
| BR (1) | BR112017011982A2 (enExample) |
| CA (1) | CA2968675C (enExample) |
| CY (1) | CY1123723T1 (enExample) |
| DK (2) | DK3230320T3 (enExample) |
| ES (2) | ES2841353T3 (enExample) |
| FI (1) | FI3808775T3 (enExample) |
| HR (2) | HRP20202034T1 (enExample) |
| HU (2) | HUE052606T2 (enExample) |
| IL (3) | IL282649B (enExample) |
| LT (2) | LT3230320T (enExample) |
| MX (1) | MX2017007636A (enExample) |
| NZ (2) | NZ731954A (enExample) |
| PL (1) | PL3808775T3 (enExample) |
| PT (2) | PT3230320T (enExample) |
| RS (2) | RS65664B1 (enExample) |
| RU (1) | RU2711729C2 (enExample) |
| SG (2) | SG11201703931QA (enExample) |
| SI (2) | SI3230320T1 (enExample) |
| SM (2) | SMT202100148T1 (enExample) |
| WO (1) | WO2016094481A1 (enExample) |
| ZA (1) | ZA201703263B (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2841353T3 (es) * | 2014-12-09 | 2021-07-08 | Regeneron Pharma | Animales no humanos que tienen un gen del grupo de diferenciación 274 humanizado |
| HUE054612T2 (hu) | 2015-11-20 | 2021-09-28 | Regeneron Pharma | Humanizált limfocitaaktiváló gén 3-t tartalmazó nem-humán állatok |
| US10582702B2 (en) | 2016-02-04 | 2020-03-10 | Regeneron Pharmaceuticals, Inc. | Non-human animals having an engineered ANGPTL8 gene |
| SG10202001578RA (en) | 2016-02-29 | 2020-04-29 | Regeneron Pharma | Rodents having a humanized tmprss gene |
| DK3476865T5 (da) | 2016-06-28 | 2024-09-09 | Biocytogen Pharmaceuticals Beijing Co Ltd | Fremgangsmåde til konstruktion af pd-1-gen-modificeret humaniseret dyremodel og anvendelse deraf |
| WO2018041120A1 (en) | 2016-08-31 | 2018-03-08 | Beijing Biocytogen Co., Ltd | Genetically modified non-human animal with human or chimeric tigit |
| CN107815467B (zh) * | 2016-08-31 | 2021-03-16 | 百奥赛图(北京)医药科技股份有限公司 | 人源化基因改造动物模型的制备方法及应用 |
| CN107815466B (zh) | 2016-08-31 | 2020-03-13 | 百奥赛图江苏基因生物技术有限公司 | 人源化基因改造动物模型的制备方法及应用 |
| DK3507373T5 (da) | 2016-08-31 | 2024-09-02 | Biocytogen Pharmaceuticals Beijing Co Ltd | Genetisk modificeret ikke-menneskeligt dyr med human eller kimær pd-l1 |
| BR112019011186A2 (pt) | 2016-12-01 | 2019-10-08 | Regeneron Pharmaceuticals, Inc. | conjugado de anticorpo radiomarcado, composto, e, métodos de imageamento e para tratamento de um tumor. |
| CN109666701B (zh) * | 2017-10-13 | 2021-08-24 | 百奥赛图(北京)医药科技股份有限公司 | 一种pd-1基因修饰人源化动物模型的构建方法及其应用 |
| WO2019072241A1 (en) | 2017-10-13 | 2019-04-18 | Beijing Biocytogen Co., Ltd | NON-HUMAN ANIMAL GENETICALLY MODIFIED WITH PD-1 HUMAN OR CHIMERIC |
| US11419318B2 (en) | 2017-11-30 | 2022-08-23 | Regeneran Pharmaceuticals, Inc. | Genetically modified rat comprising a humanized TRKB locus |
| CN109913493B (zh) | 2017-12-12 | 2021-03-16 | 百奥赛图江苏基因生物技术有限公司 | 人源化cd3基因改造动物模型的制备方法及应用 |
| JP7328243B2 (ja) | 2018-03-26 | 2023-08-16 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 治療薬を試験するためのヒト化げっ歯類 |
| SG11202011284RA (en) | 2018-07-16 | 2020-12-30 | Regeneron Pharma | Non-human animal models of ditra disease and uses thereof |
| CN110846321B (zh) * | 2018-08-21 | 2021-11-19 | 中国科学院动物研究所 | 一种突变基因及其用于构建斑色鱼鳞癣小型猪模型的用途 |
| WO2020081585A1 (en) * | 2018-10-15 | 2020-04-23 | The Brigham And Women's Hospital, Inc. | The long non-coding rna inca1 and homo sapiens heterogeneous nuclear ribonucleoprotein h1 (hnrnph1) as therapeutic targets for immunotherapy |
| CN109452229B (zh) * | 2018-11-19 | 2021-10-22 | 百奥赛图(北京)医药科技股份有限公司 | 狗源化pd-1基因改造动物模型的制备方法及应用 |
| CN109979539B (zh) * | 2019-04-10 | 2020-10-02 | 电子科技大学 | 基因序列优化方法、装置及数据处理终端 |
| CN114621971A (zh) * | 2021-02-19 | 2022-06-14 | 百奥赛图(北京)医药科技股份有限公司 | 经遗传修饰的非人动物及其构建方法和应用 |
| CN112999368A (zh) * | 2021-04-09 | 2021-06-22 | 广东药康生物科技有限公司 | 人源化模型进行药效评价方法的建立 |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5670356A (en) | 1994-12-12 | 1997-09-23 | Promega Corporation | Modified luciferase |
| US6485964B1 (en) * | 1995-03-20 | 2002-11-26 | Arris Pharmaceutical Corporation | Transgenic mammals lacking expression of erythropoietin or of erythropoietin receptor, transgenic mammals expressing chimeric erythropoietin receptors, constructs for producing the transgenic mammals and uses therefor |
| GB9517780D0 (en) | 1995-08-31 | 1995-11-01 | Roslin Inst Edinburgh | Biological manipulation |
| GB9517779D0 (en) | 1995-08-31 | 1995-11-01 | Roslin Inst Edinburgh | Biological manipulation |
| US5874304A (en) | 1996-01-18 | 1999-02-23 | University Of Florida Research Foundation, Inc. | Humanized green fluorescent protein genes and methods |
| CA2414331C (en) | 2000-06-28 | 2011-11-29 | Genetics Institute, Llc. | Pd-l2 molecules: novel pd-1 ligands and uses therefor |
| US6586251B2 (en) | 2000-10-31 | 2003-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| WO2002086083A2 (en) | 2001-04-20 | 2002-10-31 | Mayo Foundation For Medical Education And Research | Methods of enhancing cell responsiveness |
| DE10211088A1 (de) * | 2002-03-13 | 2003-09-25 | Ugur Sahin | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
| ES2350687T3 (es) | 2002-07-03 | 2011-01-26 | Ono Pharmaceutical Co., Ltd. | Composiciones de inmunopotenciación. |
| JP2006517096A (ja) * | 2002-12-16 | 2006-07-20 | ジェネンテック・インコーポレーテッド | ヒトｃｄ２０を発現するトランスジェニックマウス |
| CA2508660C (en) | 2002-12-23 | 2013-08-20 | Wyeth | Antibodies against pd-1 and uses therefor |
| ES2364335T3 (es) * | 2003-12-24 | 2011-08-31 | G2 Inflammation Pty Ltd | Mamífero no humano transgénico que comprende un polinucleótido que codifica el c5ar humano o humanizado. |
| WO2005060739A1 (en) | 2003-12-24 | 2005-07-07 | G2 Inflammation Pty Ltd | Transgenic non-human mammal comprising a polynucleotide encoding human or humanized c5ar |
| HUE070155T2 (hu) | 2004-10-06 | 2025-05-28 | Mayo Found Medical Education & Res | B7-H10 és PD-1 vesesejtes karcinóma kezelésében |
| ES2667169T3 (es) | 2004-10-19 | 2018-05-09 | Regeneron Pharmaceuticals, Inc. | Método para generar un animal no humano homocigótico para una modificación genética |
| PL1907424T3 (pl) | 2005-07-01 | 2015-12-31 | Squibb & Sons Llc | Ludzkie monoklonalne przeciwciała wobec liganda zaprogramowanej śmierci 1 (PD-L1) |
| US8216996B2 (en) | 2006-03-03 | 2012-07-10 | Ono Pharmaceutical Co., Ltd. | Multimer of extracellular domain of cell surface functional molecule |
| JP6087503B2 (ja) | 2008-09-26 | 2017-03-08 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | ヒト抗ｐｄ−１、ｐｄ−ｌ１、及びｐｄ−ｌ２抗体とその用途 |
| CN102575227A (zh) | 2008-10-08 | 2012-07-11 | 英特瑞克斯顿股份有限公司 | 表达多种免疫调节剂的工程改造细胞及其应用 |
| CN112690250B (zh) * | 2008-12-18 | 2024-03-08 | 伊拉兹马斯大学鹿特丹医学中心 | 表达人源化抗体的非人转基因动物及其用途 |
| JP5844159B2 (ja) | 2009-02-09 | 2016-01-13 | ユニヴェルシテ デクス−マルセイユＵｎｉｖｅｒｓｉｔｅ Ｄ’Ａｉｘ−Ｍａｒｓｅｉｌｌｅ | Ｐｄ−１抗体およびｐｄ−ｌ１抗体ならびにその使用 |
| RU2425880C2 (ru) * | 2009-07-30 | 2011-08-10 | Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН | Способ получения трансгенных мышей |
| US8518392B2 (en) | 2009-08-14 | 2013-08-27 | Regeneron Pharmaceuticals, Inc. | Promoter-regulated differentiation-dependent self-deleting cassette |
| AU2010286516B2 (en) * | 2009-08-28 | 2016-10-06 | Regeneron Pharmaceuticals, Inc. | Antikine antibodies that bind to multiple CC chemokines |
| ES2700852T3 (es) | 2009-10-06 | 2019-02-19 | Regeneron Pharma | Ratones modificados genéticamente e injerto |
| US20120263692A1 (en) | 2009-11-16 | 2012-10-18 | Bertone Alicia L | Engineered Xenogeneic Cells for Repair of Biological Tissue |
| RU2706200C2 (ru) * | 2009-11-24 | 2019-11-14 | Медиммьюн Лимитед | Специфические связывающие агенты против в7-н1 |
| NO2516457T3 (enExample) * | 2009-12-21 | 2018-08-11 | ||
| US8507663B2 (en) * | 2010-04-06 | 2013-08-13 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of CD274/PD-L1 gene |
| CN105861553B (zh) | 2011-02-15 | 2020-08-14 | 再生元制药公司 | 人源化m-csf小鼠 |
| HUE035652T2 (en) * | 2011-10-28 | 2018-05-28 | Regeneron Pharma | Genetically modified major histocompatibility complex mice |
| KR102113108B1 (ko) | 2011-10-28 | 2020-05-20 | 리제너론 파아마슈티컬스, 인크. | 키메라 주요 조직적합성 복합체 （ｍｈｃ） 제ｉｉ부류 분자들을 발현하는 유전자전이 마우스 |
| DK2663575T3 (en) | 2011-10-28 | 2014-12-15 | Regeneron Pharma | HUMANIZED IL-6 and IL-6 receptor |
| WO2013078230A1 (en) | 2011-11-23 | 2013-05-30 | The Trustees Of The University Of Pennsylvania | Use of pdl1 expressing cells to convert t cells into regulatory t cells |
| CN103987405B (zh) | 2011-11-28 | 2017-03-29 | 默克专利股份公司 | 抗pd‑l1抗体及其用途 |
| CN111499755A (zh) | 2012-08-03 | 2020-08-07 | 丹娜法伯癌症研究院 | 抗-pd-l1和pd-l2双结合抗体单一试剂及其使用方法 |
| US20140047572A1 (en) * | 2012-08-13 | 2014-02-13 | University Of Rochester | Thrombopoietin mimetics for the treatment of radiation or chemical induced bone marrow injury |
| ES2701093T3 (es) | 2012-08-21 | 2019-02-20 | Sanofi Biotechnology | Métodos para tratar o prevenir el asma administrando un antagonista de IL-4R |
| IL307969B1 (en) | 2012-09-07 | 2025-10-01 | Regeneron Pharma | Genetically modified non-human animals and methods of using them |
| CA2887706C (en) | 2012-11-05 | 2022-08-02 | Regeneron Pharmaceuticals | Genetically modified non-human animals and methods of use thereof |
| EP2948475A2 (en) | 2013-01-23 | 2015-12-02 | AbbVie Inc. | Methods and compositions for modulating an immune response |
| CN109913495B (zh) | 2013-02-20 | 2022-11-25 | 瑞泽恩制药公司 | 大鼠的遗传修饰 |
| WO2014130671A1 (en) * | 2013-02-20 | 2014-08-28 | Regeneron Pharmaceuticals, Inc. | Mice expressing humanized t-cell co-receptors |
| US20150342163A1 (en) | 2013-02-22 | 2015-12-03 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex mice |
| KR102211267B1 (ko) | 2013-02-22 | 2021-02-04 | 리제너론 파아마슈티컬스, 인크. | 사람화된 주요 조직적합성 복합체를 발현하는 마우스 |
| SI2986729T1 (sl) * | 2013-04-16 | 2019-02-28 | Regeneron Pharmaceuticals, Inc. | Ciljana sprememba genoma podgane |
| CN103242448B (zh) * | 2013-05-27 | 2015-01-14 | 郑州大学 | 一种全人源化抗pd-1单克隆抗体及其制备方法和应用 |
| WO2014197369A1 (en) | 2013-06-06 | 2014-12-11 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for identification, assessment prevention, and treatment of cancer using pd-l1 isoforms |
| RU2018136614A (ru) | 2013-09-23 | 2018-11-27 | Регенерон Фармасьютикалс, Инк. | Отличные от человека животные с гуманизированным геном сигнального регуляторного белка |
| EP3071024B1 (en) | 2013-11-19 | 2018-09-05 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized b-cell activating factor gene |
| TWI680138B (zh) * | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗ｐｄ-ｌ１之人類抗體 |
| ES2794942T3 (es) | 2014-04-08 | 2020-11-19 | Regeneron Pharma | Animales no humanos que tienen receptores Fc-gamma humanizados |
| NO2785538T3 (enExample) | 2014-05-07 | 2018-08-04 | ||
| DK3145307T3 (en) | 2014-05-19 | 2019-04-15 | Regeneron Pharma | RE-MODIFIED NON-HUMAN ANIMALS EXPRESSING HUMAN EPO |
| SG11201609638RA (en) | 2014-06-19 | 2016-12-29 | Regeneron Pharma | Non-human animals having a humanized programmed cell death 1 gene |
| PL3223605T3 (pl) | 2014-11-24 | 2021-04-19 | Regeneron Pharmaceuticals, Inc. | Zwierzęta inne niż ludzie eksprymujące humanizowany kompleks CD3 |
| DK3466255T3 (da) | 2014-12-05 | 2021-05-03 | Regeneron Pharma | Ikke-humane dyr med en humaniseret klynge af differentiering af 47-gen |
| ES2841353T3 (es) | 2014-12-09 | 2021-07-08 | Regeneron Pharma | Animales no humanos que tienen un gen del grupo de diferenciación 274 humanizado |
| HUE054612T2 (hu) | 2015-11-20 | 2021-09-28 | Regeneron Pharma | Humanizált limfocitaaktiváló gén 3-t tartalmazó nem-humán állatok |
| DK3507373T5 (da) | 2016-08-31 | 2024-09-02 | Biocytogen Pharmaceuticals Beijing Co Ltd | Genetisk modificeret ikke-menneskeligt dyr med human eller kimær pd-l1 |
-
2015
- 2015-12-09 ES ES15816631T patent/ES2841353T3/es active Active
- 2015-12-09 LT LTEP15816631.4T patent/LT3230320T/lt unknown
- 2015-12-09 EP EP24167621.2A patent/EP4399969A3/en active Pending
- 2015-12-09 ES ES20194168T patent/ES2982515T3/es active Active
- 2015-12-09 SM SM20210148T patent/SMT202100148T1/it unknown
- 2015-12-09 IL IL282649A patent/IL282649B/en unknown
- 2015-12-09 SG SG11201703931QA patent/SG11201703931QA/en unknown
- 2015-12-09 EP EP15816631.4A patent/EP3230320B1/en active Active
- 2015-12-09 FI FIEP20194168.9T patent/FI3808775T3/fi active
- 2015-12-09 RS RS20240717A patent/RS65664B1/sr unknown
- 2015-12-09 HR HRP20202034TT patent/HRP20202034T1/hr unknown
- 2015-12-09 PT PT158166314T patent/PT3230320T/pt unknown
- 2015-12-09 DK DK15816631.4T patent/DK3230320T3/da active
- 2015-12-09 RS RS20201547A patent/RS61218B1/sr unknown
- 2015-12-09 HU HUE15816631A patent/HUE052606T2/hu unknown
- 2015-12-09 KR KR1020177016266A patent/KR102316842B1/ko active Active
- 2015-12-09 HR HRP20240855TT patent/HRP20240855T1/hr unknown
- 2015-12-09 CN CN202110688677.9A patent/CN113412818B/zh active Active
- 2015-12-09 NZ NZ731954A patent/NZ731954A/en unknown
- 2015-12-09 SI SI201531463T patent/SI3230320T1/sl unknown
- 2015-12-09 NZ NZ770783A patent/NZ770783A/en unknown
- 2015-12-09 HU HUE20194168A patent/HUE067123T2/hu unknown
- 2015-12-09 LT LTEP20194168.9T patent/LT3808775T/lt unknown
- 2015-12-09 US US14/963,402 patent/US9913461B2/en active Active
- 2015-12-09 SI SI201532021T patent/SI3808775T1/sl unknown
- 2015-12-09 EP EP20194168.9A patent/EP3808775B1/en active Active
- 2015-12-09 MX MX2017007636A patent/MX2017007636A/es unknown
- 2015-12-09 KR KR1020217033684A patent/KR102457921B1/ko active Active
- 2015-12-09 SM SM20240313T patent/SMT202400313T1/it unknown
- 2015-12-09 JP JP2017530591A patent/JP2018500896A/ja not_active Withdrawn
- 2015-12-09 AU AU2015360667A patent/AU2015360667B2/en active Active
- 2015-12-09 RU RU2017123754A patent/RU2711729C2/ru active
- 2015-12-09 PL PL20194168.9T patent/PL3808775T3/pl unknown
- 2015-12-09 BR BR112017011982A patent/BR112017011982A2/pt not_active Application Discontinuation
- 2015-12-09 CA CA2968675A patent/CA2968675C/en active Active
- 2015-12-09 CN CN201580067025.6A patent/CN107257624B/zh active Active
- 2015-12-09 WO PCT/US2015/064626 patent/WO2016094481A1/en not_active Ceased
- 2015-12-09 DK DK20194168.9T patent/DK3808775T3/da active
- 2015-12-09 SG SG10202100792XA patent/SG10202100792XA/en unknown
- 2015-12-09 PT PT201941689T patent/PT3808775T/pt unknown
-
2017
- 2017-05-11 ZA ZA2017/03263A patent/ZA201703263B/en unknown
- 2017-06-06 IL IL252695A patent/IL252695B/en active IP Right Grant
-
2018
- 2018-01-30 US US15/883,477 patent/US10881086B2/en active Active
-
2020
- 2020-07-06 IL IL275864A patent/IL275864B/en active IP Right Grant
- 2020-10-05 JP JP2020168478A patent/JP7145920B2/ja active Active
- 2020-12-03 US US17/110,868 patent/US12089575B2/en active Active
- 2020-12-23 CY CY20201101215T patent/CY1123723T1/el unknown
-
2021
- 2021-12-16 AU AU2021286369A patent/AU2021286369B2/en active Active
-
2022
- 2022-09-20 JP JP2022148949A patent/JP7488861B2/ja active Active
-
2024
- 2024-08-15 US US18/805,786 patent/US20240389563A1/en active Pending
-
2025
- 2025-06-24 AU AU2025204751A patent/AU2025204751A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018500896A5 (enExample) | ||
| JP2017521060A5 (enExample) | ||
| RU2017123754A (ru) | Не относящиеся к человеку животные, имеющие гуманизированный ген кластера дифференцировки 274 | |
| JP2021094035A5 (enExample) | ||
| Tummala et al. | Poly (A)-specific ribonuclease deficiency impacts telomere biology and causes dyskeratosis congenita | |
| KR102617691B1 (ko) | 인간화 분화 클러스터 47 유전자를 가진 비인간 동물 | |
| JP2018533963A5 (enExample) | ||
| Zemljic-Harpf et al. | Cardiac-myocyte-specific excision of the vinculin gene disrupts cellular junctions, causing sudden death or dilated cardiomyopathy | |
| RU2016149434A (ru) | Животные, отличные от человека, имеющие гуманизированный ген 1 запрограммированный гибели клеток | |
| JP2018500012A5 (enExample) | ||
| Pravenec et al. | Recent progress in the genetics of spontaneously hypertensive rats | |
| HRP20231121T1 (hr) | Životinje koje nisu ljudi, koje imaju gen za humanizirani protein koji regulira signale | |
| JP2015523863A5 (enExample) | ||
| JP2019505216A5 (enExample) | ||
| JP2018533963A (ja) | ヒト化されたｌｙｍｐｈｏｃｙｔｅ−ａｃｔｉｖａｔｉｏｎ ｇｅｎｅ ３遺伝子を有する非ヒト動物 | |
| EP3585445B1 (en) | Humanized model of kidney and liver disorders | |
| IL314733A (en) | Humanized rodents for testing therapeutic agents | |
| JP2017213006A5 (enExample) | ||
| JP2019511918A5 (enExample) | ||
| JP2016519138A5 (enExample) | ||
| US20230413791A1 (en) | Non-human animals having a humanized clec9a gene | |
| US20220192165A1 (en) | Non-human animals having a humanized tslp gene, a humanized tslp receptor gene, and/or a humanized il7ra gene | |
| Ma et al. | Retinoid X receptor alpha is a spatiotemporally-specific therapeutic target for doxorubicin-induced cardiomyopathy in adult zebrafish | |
| Thompson | Gene expression evolution after duplication | |
| HK40012890B (en) | Humanized model of kidney and liver disorders |